Product Sales (Tables)

3 Months Ended

Mar. 31, 2019

Net product sales consist of the following:



	Three Months Ended March 31,
Net Product Sales in the United States	2019		2018
EYLEA^®	$	1,074.1	$	984.0
Libtayo^®	26.8		—
ARCALYST^®	3.5		3.9
	$	1,104.4	$	987.9

Revenue earned in connection with our Bayer EYLEA collaboration is as follows (note that the table excludes amounts in connection with our Bayer Ang2 antibody and PDGFR-beta antibody collaboration agreements, which were previously terminated):



	Three Months Ended March 31,
Bayer EYLEA Collaboration Revenue	2019		2018
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	249.3	$	232.1
Reimbursement of Regeneron EYLEA development expenses	2.6		3.5
Other	24.3		11.8
	$	276.2	$	247.4

The collaboration revenue we earned from Sanofi is detailed below:



	Three Months Ended March 31,
Sanofi Collaboration Revenue	2019			2018
Antibody:
Reimbursement of Regeneron research and development expenses	$	74.5		$	60.4
Reimbursement of Regeneron commercialization-related expenses	116.6			85.4
Regeneron's share of losses in connection with commercialization of antibodies	(27.8		)	(74.8		)
Other	12.9			17.3
Total Antibody	176.2			88.3
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	46.4			73.8
Reimbursement of Regeneron commercialization-related expenses	2.3			1.2
Other	21.5			26.2
Total Immuno-oncology	70.2			101.2
	$	246.4		$	189.5

Schedules of Concentration of Risk, by Risk Factor

The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the three months ended March 31, 2019 and 2018. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:

Sales Related Deductions Activity

The following table summarizes the provisions, and credits/payments, for these sales-related deductions during the three months ended March 31, 2019 and 2018.



	Rebates, Chargebacks, and Discounts			Distribution- Related Fees			Other Sales- Related Deductions			Total
Balance as of December 31, 2018	$	41.1		$	42.0		$	8.3		$	91.4
Provisions	78.6			52.8			16.1			147.5
Credits/payments	(60.8		)	(47.9		)	(0.4		)	(109.1		)
Balance as of March 31, 2019	$	58.9		$	46.9		$	24.0		$	129.8

Balance as of December 31, 2017	$	29.9		$	34.1		$	21.3		$	85.3
Provisions	48.5			51.7			11.2			111.4
Credits/payments	(30.7		)	(42.0		)	(14.7		)	(87.4		)
Balance as of March 31, 2018	$	47.7		$	43.8		$	17.8		$	109.3

Three Months Ended
March 31,

Besse Medical, a subsidiary of AmerisourceBergen Corporation

McKesson Corporation